Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Performing integrative transcriptomic and chemical screening to identify patient-specific vulnerabilities in poor-prognosis acute myeloid leukemia].

[Rinsho ketsueki] The Japanese journal of clinical hematology - 1 Jan 2021

Hashimoto Mari, Ishikawa Fumihiko

Abstract excerpt

Genetic complexity and heterogeneity have made drug discovery difficult in human malignancies. In the past few years, we aimed to find vulnerabilities in therapy-resistant and refractory acute myeloid leukemia (AML) through integrative analyses of genomic data, clinical information, and results from in vivo/in vitro cell biological assays. Through analyses, we found that the cells of patients with AML show...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to fms-Like Tyrosine Kinase 3
Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Prognosis

Share to Transcriptome

Source

Identifiers

PMID: 34349062
DOI: 10.11406/rinketsu.62.774

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Performing integrative transcriptomic and chemical screening to identify patient-specific vulnerabilities in poor-prognosis acute myeloid leukemia].PMID 34349062Read ↗

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia.Semantic proximity Read ↗

A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid LeukemiaSemantic proximity Read ↗

Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision MedicineSemantic proximity Read ↗

Patient-tailored design of AML cell subpopulation-selective drug combinationsSemantic proximity Read ↗

Dynamic heterogeneity towards drug resistance in AML cells is primarily driven by epigenomic mechanism unveiled by multi-omics analysisSemantic proximity Read ↗

Identification of novel genetic vulnerabilities and therapeutic targets in acute myeloid leukaemia using CRISPR dropout screensSemantic proximity Read ↗

Advancements in targeted therapies for acute myeloid leukemia.Semantic proximity Read ↗

Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemiaSemantic proximity Read ↗

A Single-Cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Integrated Genomics Reveal Potential Resistance Mechanisms of PANoptosis‐Associated Genes in Acute Myeloid LeukemiaSemantic proximity Read ↗

Group comparison based on genetic information reveals lineage-specific therapeutic vulnerabilities in acute myeloid leukemiaSemantic proximity Read ↗

Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.